Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

and the need for liver transplant 3 Additionally, Novo Nordisk's application for Wegovy ® (semaglutide) injection 2.4 mg for the treatment of metabolic dysfunction-associated steatohepatitis ...

25 mg oral formulation of Wegovy ® (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% ... The NDA is supported by data from the phase 3 OASIS 4 trial (ClinicalTrials.gov Identifier ...

Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion of patients with MASH achieved resolution of ...

"We are entering a new era of obesity care where patients want individualized treatment plans that address their needs and provide choices, including oral formulations," said Anna Windle, PhD ...

ESSENCE is a phase 3 trial evaluating the effect of once-weekly subcutaneous semaglutide 2.4 mg in adults with metabolic dysfunction-associated steatohepatitis with moderate to advanced liver ...